Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04562272
Other study ID # 15849/20
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 21, 2020
Est. completion date December 31, 2023

Study information

Verified date September 2020
Source Institute for Clinical and Experimental Medicine
Contact Marek Sramko, MD, PhD
Phone +420731682681
Email marek.sramko@ikem.cz
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with anterior wall AMI treated by PCI will undergo, after successful revascularization of the infarct artery, measurement of the left ventricular pressure, and femoral angiogram. Patients with elevated LV pressure and adequate femoral access will be randomized to standard pharmacological treatment of AMI vs. mechanical unloading by Impella-CP (on top of the standard treatment) for 36-48 hours. LV unloading will be guided by measurement of PCWP by Swan-Ganz catheter. On the day 4-7, and at 3 months after the AMI, the patients will undergo SPECT and 3D-echocardiography to assess ventricular remodeling and extent of the post-infarct scar. The patients will be followed for at least 12 months for the occurrence of heart failure and adverse cardiovascular events. The study will test the hypothesis, whether the LV mechanical unloading after PCI will attenuate post-infarct scar and cardiac remodeling.


Description:

1. Eligible patients with be screened before PCI

2. The patients with undergo coronary angiography and PCI according to common medical practice

3. At the end of the PCI procedure, after a successful revascularization, a pigtail catheter will be used to measure LV filling pressure and to perform femoral angiography (to evaluate femoral access).

4. Patients fulfilling angiographic and hemodynamic criteria will be randomized 1:1 to standard care vs. mechanical unloading by Impella-CP.

5. The patients will be treated on a CCU with experience with use of Impella-CP.

6. On the CCU, all patients will be monitored by a Swan-Ganz catheter for 48 hours.

7. The pump speed will be adjusted to maintain the lowest tolerated PCWP while avoiding suction events.

8. Mechanical unloading will last 36-48h. Afterwards, the Impella-CP will be explanted.

9. All patients will receive standard pharmacotherapy of AMI, according to the guidelines.

10. Revascularization of significant non-infarct lesions will be performed during the index hospitalization.

11. 3D-echocardiography and Tc-SPECT (D-SPECT) will be performed on the day 5-7 of the index hospitalization. LV phasic volumes and extent of nonperfused myocardium (scar) will be evaluated automatically, using software provided by the vendor.

12. 3D-echocardiography and Tc-SPECT will be repeated at 3 months after the AMI.

13. The patients will be followed by out-patient check-ups every 12 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- large anterior wall AMI with estimated ischemia of <24h

- at risk of the beginning of cardiogenic shock (SCAI A/B)

- blood pressure <160/100 mmHg

- no previous IM based on the patient's history

- no previously known LV systolic dysfunction

- assumed new LV dysfunction documented by ECHO or LVG (LVEF < 45%)

- infarct culprit lesion at the proximal LAD, LMCA or equivalent, with TIMI <= 2 flow

- LV end-diastolic pressure of >= 18 mmHg measured invasively

Exclusion Criteria:

- history of chronic LV dysfunction

- chronic anticoagulation therapy

- the need of IIb/IIIa blockers at the PCI

- inadequate femoral vein access (peripheral artery disease)

- significant valve disease or valve prosthesis

- CPR >5 min before PCI

- LV thrombus

- periprocedural AMI (obliteration of large non-culprit artery during PCI)

Study Design


Intervention

Procedure:
LV mechanical unloading by Impella-CP
The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)

Locations

Country Name City State
Czechia Institute for Clinical and Experimental Medicine (IKEM) Prague

Sponsors (1)

Lead Sponsor Collaborator
Institute for Clinical and Experimental Medicine

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Other self-assessed dyspnea dyspnea reported by the patient on a Likert scale day 1, 2 and 5
Other lung water assessment of lung water score by ultrasound day 1, 2 and 5
Other maximum hs-TnT, BNP, serum lactate diference in hs-TnT, BNP and lactate between the groups during the first 5 day after AMI
Primary Difference in the left ventricular end-systolic volume Absolute change in the LVESV measured by SPECT and compared between the groups LV end-systolic volume measured during the index hospitalization (day 5-7) and at 3 months
Primary Occurrence of LV remodeling Occurrence of LV remodeling defined by the increase of LV end-systolic volume >20% LV end-systolic volume measured during the index hospitalization (day 5-7) and at 3 months
Primary Extent of post-infarct scar Extent of post-infarct scar measured by Tc-SPECT and compared between the groups LV scar extent measured during the index hospitalization (day 5-7) and at 3 months
Secondary CV complications occurence of TIMI bleeding, hemolysis, thromboembolic events during the first 5 day after AMI
Secondary heart failure acute heart failure requiring inotropes or progression of cardiogenic shock during the first 5 day after AMI
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Completed NCT04507529 - Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients N/A
Recruiting NCT06066970 - Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
Recruiting NCT03620266 - Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI N/A
Completed NCT04097912 - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT03668587 - Feasibility and Security of a Rapid Rule-out and rule-in Troponin Protocol in the Management of NSTEMI in an Emergency Departement
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Recruiting NCT05371470 - Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT06007950 - Time-restricted Eating Study (TRES): Impacts on Anthropometric, Cardiometabolic and Cardiovascular Health N/A
Withdrawn NCT05327855 - Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) Phase 2
Recruiting NCT02876952 - High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients N/A
Completed NCT02917213 - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed NCT02711631 - Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation N/A
Completed NCT02552407 - Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis N/A
Completed NCT02382731 - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction N/A
Completed NCT02305602 - A Study of VentriGel in Post-MI Patients Phase 1